Edison Investment Research - Siga Technologies Inc. (SIGA) SIGA Technologies - TPOXX chalks up another DoD contract win

Report

Edison Investment Research

Sean Conroy

SIGA Technologies - TPOXX chalks up another DoD contract win

SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for a total of approximately $28m and adds to the already robust H224 orderbook of c $154m of outstanding TPOXX orders, following the July 2024 $112.5m option exercise from the Biomedical Advanced Research and Development Authority (BARDA) for oral TPOXX. While delivery timeline details are yet to be disclosed, we expect this new DoD order to at least start being partially serviced in FY25. The DoD has also provided $27m in R&D support to the post-exposure prophylaxis (PEP) development effort, for which the regulatory filing is planned within the next 12 months.

23/08/2024 1 EN

Underlying

Siga Technologies Inc.

SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The company's primary product is an oral formulation of TPOXX?, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The United States Food and Drug Administration has approved oral TPOXX? for the treatment of smallpox.

See profile

US8269171067 NASDAQ Stock Market United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

GlobeNewsWire

TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses

TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor to supply TEPOXX to Japan’s national stockpileComprehensive data package demonstrates strong safety profile and robust preclinical efficacy NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, a commercial stage pharmaceutical company, announced today that its antiviral treatment TEPOXX (tecovirim...

January 2, 2025 January 2, 2025 1 EN

GlobeNewsWire

Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced

Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults affirm tecovirimat’s strong safety profileEfficacy in patients with more severe disease not assessed in study NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analy...

December 10, 2024 December 10, 2024 1 EN

Edison Investment Research

SIGA Technologies - Strong order book moving into Q424

SIGA Technologies reported revenues of $10m in Q324, attributed primarily to deliveries under the $112.5m BARDA option, exercised in July 2024. Backed by a strong order book ($146m at end-Q324), the sales momentum has picked up pace in Q424 with another $51.2m and $8.5m of oral and IV TPOXX (IVT) delivered to the Strategic National Stockpile (SNS) in October 2024. We expect further deliveries in Q424 and early 2025 under the BARDA contract as well as the $9m US Department of Defense (DoD) order received in August 2024. Q424 also marked SIGA’s first commercial foray into Africa (delivering oral...

November 18, 2024 November 18, 2024 1 EN

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Pedro Fonseca

Pedro Fonseca

Baillie Gifford US Growth Trust - A unique high-growth strategy meriting support

Baillie Gifford US Growth Trust (USA) invests in exceptional US businesses with the potential to grow substantially faster than the market and deliver above-market returns. Such businesses tend to operate at the cutting edge of technology-led change and USA has exposure to companies focused on AI, space travel and online services. This note reiterates USA’s unique investment proposition and scrutinises a recent proposal from Saba, a US hedge fund manager, aimed at ousting USA’s board and replacing its investment managers. Saba currently owns less than 28% of USA shares in issue. The trust’s bo...

January 10, 2025 January 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

Greggs - More challenging environment in H224

Greggs has reported that FY24 profit is in line with management’s expectation despite the more challenging environment and slowing sales growth through H224. The more challenging market means that management is more cautious about the outlook for H125 than previously. With space expansion and recovery of cost inflation, it expects to deliver profit growth in FY25 albeit lower than previously anticipated. We have reduced our FY25 profit before tax estimate by c 2%.

January 9, 2025 January 9, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

SIGA Technologies - TPOXX chalks up another DoD contract win

TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses

Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced

SIGA Technologies - Strong order book moving into Q424

Topps Tiles - Accelerating growth through Q125

Baillie Gifford US Growth Trust - A unique high-growth strategy meriting support

Greggs - More challenging environment in H224

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe